LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Inicio・Lista de Acciones・Sana Biotechnology Inc

Sana Biotechnology Inc

Cerrado

SectorSanidad

3.04 -1.3

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.9699999999999998

Máximo

3.13

Métricas clave
By Trading Economics
Ingresos	12M -47M
BPA	-0.171
Empleados	142
EBITDA	23M -35M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+182.74% upside

Dividendos
By Dow Jones
Próximas Ganancias	7 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-115M 846M
Apertura anterior	4.34
Cierre anterior	3.04

Noticias sobre sentimiento de mercado

By Acuity

25%

75%

49 / 345 Clasificación en Healthcare

Sana Biotechnology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

25 may 2026, 08:24 UTC

Principales Movimientos del Mercado

Adquisiciones, fusiones, absorciones

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 may 2026, 21:22 UTC

Ganancias

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 may 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Basic Materials Roundup: Market Talk

25 may 2026, 16:20 UTC

Charlas de Mercado

Ganancias

Basic Materials Roundup: Market Talk

25 may 2026, 16:01 UTC

Charlas de Mercado

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 may 2026, 14:43 UTC

Charlas de Mercado

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 may 2026, 14:15 UTC

Charlas de Mercado

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 may 2026, 13:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

25 may 2026, 12:58 UTC

Charlas de Mercado

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 may 2026, 12:56 UTC

Charlas de Mercado

Ganancias

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 may 2026, 12:48 UTC

Charlas de Mercado

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 may 2026, 12:48 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

25 may 2026, 12:34 UTC

Charlas de Mercado

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 may 2026, 12:10 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Delivery Hero's Assets Look Strategic -- Market Talk

25 may 2026, 11:00 UTC

Charlas de Mercado

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 may 2026, 10:19 UTC

Charlas de Mercado

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 may 2026, 10:05 UTC

Ganancias

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 may 2026, 10:04 UTC

Ganancias

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 may 2026, 10:03 UTC

Ganancias

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 may 2026, 10:02 UTC

Ganancias

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 may 2026, 10:01 UTC

Ganancias

Tenaga Nasional 1Q Net Up 3.7% on Year

25 may 2026, 10:00 UTC

Ganancias

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 may 2026, 09:56 UTC

Ganancias

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 may 2026, 09:56 UTC

Ganancias

Tenaga Nasional 1Q EPS MYR0.1883

25 may 2026, 09:56 UTC

Ganancias

Tenaga Nasional 1Q Rev MYR17.1B

25 may 2026, 09:56 UTC

Ganancias

Tenaga Nasional 1Q Net MYR1.1B

25 may 2026, 09:38 UTC

Charlas de Mercado

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 may 2026, 09:33 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

25 may 2026, 09:33 UTC

Charlas de Mercado

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 may 2026, 08:55 UTC

Charlas de Mercado

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Comparación entre iguales

Cambio de precio

Sana Biotechnology Inc previsión

Precio Objetivo

By TipRanks

182.74% repunte

Estimación a 12 Meses

Media 8.68 USD 182.74%

Máximo 16 USD

Mínimo 3.07 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sana Biotechnology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Sana Biotechnology Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

49 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.